General Information of Drug (ID: DMU4G9J)

Drug Name
CAR-T cells targeting PSCA Drug Info
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMU4G9J

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Anti-PSCA mab DMJPZDC Pancreatic cancer 2C10 Phase 2 [3]
BPX-601 DMV9QGW Gastric adenocarcinoma 2B72 Phase 1/2 [4]
GEM3PSCA DM3GSPR Non-small-cell lung cancer 2C25 Phase 1 [5]
MB-105 DMVGTP6 Prostate cancer 2C82.0 Phase 1 [6]
Anti-PSCA mab DMJPZDC Pancreatic cancer 2C10 Phase 2 [3]
BPX-601 DMV9QGW Gastric adenocarcinoma 2B72 Phase 1/2 [4]
GEM3PSCA DM3GSPR Non-small-cell lung cancer 2C25 Phase 1 [5]
MB-105 DMVGTP6 Prostate cancer 2C82.0 Phase 1 [6]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostate stem cell antigen (PSCA) TT9T4AV PSCA_HUMAN CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
2 ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
3 Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71.
4 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
5 Clinical pipeline report, company report or official report of Gemoab.
6 Clinical pipeline report, company report or official report of Mustang Bio.